Background: Current vancomycin dosing guidelines recommend targeting trough concentrations of 15-20 mg/L in complicated infections to avoid treatment failure and resistance. How to accomplish this in the intermittent hemodialysis (IHD) population has not been adequately described. A weight-based vancomycin dosing protocol for IHD patients was developed to provide standardization of vancomycin dosing for this patient population. Prior to implementation of this protocol, clinical pharmacists used their individual judgment for dosing and monitoring.
Objective: Compare achievement of goal (15-20 mg/L) pre-IHD vancomycin levels between a group of patients dosed prior to implementation of this weight-based vancomycin dosing protocol and a group dosed after implementation.
Methods: This retrospective study evaluated hospitalized IHD patients who received vancomycin and had an appropriate pre-IHD vancomycin level. Any patients with acute kidney injury or who required continuous renal replacement therapy or peritoneal dialysis were excluded.
Results: A total of 145 vancomycin courses (94 pre-protocol and 51 post-protocol) were included in this study. The post-protocol group had an increased percentage of patients who achieved a pre-IHD vancomycin level of 15-20 mg/L. We also found improvement in pre-IHD vancomycin levels attained in patients weighing less than 75 kg and the need for additional study in patients weighing more than 105 kg.
Conclusion: Simplifying and standardizing vancomycin dosing for hospitalized IHD patients based on weight resulted in 37% of patients achieving goal pre-IHD vancomycin level of 15-20 mg/L with zero patients having a pre-IHD vancomycin level <10 mg/L.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/0886022X.2016.1229992 | DOI Listing |
Front Pharmacol
December 2024
Department of Burn, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Objective: To analyze factors influencing the vancomycin trough concentration in burn patients to provide a basis for the more rational use of vancomycin in these patients.
Materials And Methods: We collected the clinical data of adult burn patients treated with vancomycin in a Chinese hospital. Vancomycin was administered at a dosing regimen of 1.
Sci Rep
December 2024
Internal Medicine Department - Nephrology, Botucatu School of Medicine, University São Paulo State-UNESP, District of Rubiao Junior, Botucatu, Sao Paulo, Brazil.
The pharmacokinetics and pharmacodynamics (PK/PD) of vancomycin change during HD, increasing the risk of subtherapeutic concentrations. The aim of this study was to evaluate during and after the conventional and prolonged hemodialysis sessions to identify the possible risk of the patient remaining without adequate antimicrobial coverage during therapy. Randomized, non-blind clinical trial, including critically ill adults with septic AKI on conventional (4 h) and prolonged HD (6 and 10 h) and using vancomycin for at least 72 h.
View Article and Find Full Text PDFBackground: The most severe complications of antibiotic use are clostridial infection (CDI) and pseudomembranous colitis (PMC). There is a need for further study of these conditions and identification of their triggers.
Aim: To identify risk factors for severe forms of antibiotic-associated diarrhea caused by .
Front Med (Lausanne)
December 2024
Department of Pharmacy, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China.
Background: Due to its potent antibacterial activity, vancomycin is widely used in the treatment of sepsis. Therapeutic drug monitoring (TDM) can optimize personalized vancomycin dosing regimens, enhancing therapeutic efficacy and minimizing nephrotoxic risk, thereby potentially improving patient outcomes. However, it remains uncertain whether TDM affects the mortality rate among sepsis patients or whether age plays a role in this outcome.
View Article and Find Full Text PDFClin Pharmacokinet
December 2024
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Background And Objective: Vancomycin is a glycopeptide antibiotic used for the treatment of severe gram-positive infections. Despite decades of clinical experience, optimized dosing for vancomycin in pediatric populations still warrants further investigation. Patients admitted to the pediatric intensive care unit (PICU) after cardiac surgery are often treated with vancomycin in case of (suspected) infection.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!